We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Neogen (NEOG) Q1 Earnings
Read MoreHide Full Article
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.05 per share, reflecting a decline of 28.6% compared to the same period last year. Revenues are forecasted to be $203.18 million, representing a year-over-year decrease of 6.4%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Neogen metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Food Safety- Natural Toxins & Allergens' should arrive at $18.68 million. The estimate points to a change of -8.3% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Food Safety- Bacterial & General Sanitation' reaching $38.70 million. The estimate points to a change of -3% from the year-ago quarter.
Analysts predict that the 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' will reach $76.43 million. The estimate suggests a change of -6.5% year over year.
The average prediction of analysts places 'Revenues- Animal Safety- Veterinary Instruments & Disposables' at $13.94 million. The estimate points to a change of +11.3% from the year-ago quarter.
Analysts forecast 'Revenues- Animal Safety- Animal Care & Other' to reach $8.16 million. The estimate suggests a change of +22.1% year over year.
It is projected by analysts that the 'Revenues- Food Safety' will reach $146.62 million. The estimate suggests a change of -8% year over year.
According to the collective judgment of analysts, 'Revenues- Animal Safety- Genomics Services' should come in at $4.42 million. The estimate indicates a change of -72.2% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Food Safety- Genomics Services' of $13.26 million. The estimate indicates a change of +137.3% from the prior-year quarter.
The consensus estimate for 'Revenues- Animal Safety' stands at $54.65 million. The estimate suggests a change of -5.2% year over year.
Neogen shares have witnessed a change of +5.4% in the past month, in contrast to the Zacks S&P 500 composite's +4.3% move. With a Zacks Rank #4 (Sell), NEOG is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Neogen (NEOG) Q1 Earnings
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.05 per share, reflecting a decline of 28.6% compared to the same period last year. Revenues are forecasted to be $203.18 million, representing a year-over-year decrease of 6.4%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Neogen metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Food Safety- Natural Toxins & Allergens' should arrive at $18.68 million. The estimate points to a change of -8.3% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Food Safety- Bacterial & General Sanitation' reaching $38.70 million. The estimate points to a change of -3% from the year-ago quarter.
Analysts predict that the 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' will reach $76.43 million. The estimate suggests a change of -6.5% year over year.
The average prediction of analysts places 'Revenues- Animal Safety- Veterinary Instruments & Disposables' at $13.94 million. The estimate points to a change of +11.3% from the year-ago quarter.
Analysts forecast 'Revenues- Animal Safety- Animal Care & Other' to reach $8.16 million. The estimate suggests a change of +22.1% year over year.
It is projected by analysts that the 'Revenues- Food Safety' will reach $146.62 million. The estimate suggests a change of -8% year over year.
According to the collective judgment of analysts, 'Revenues- Animal Safety- Genomics Services' should come in at $4.42 million. The estimate indicates a change of -72.2% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Food Safety- Genomics Services' of $13.26 million. The estimate indicates a change of +137.3% from the prior-year quarter.
The consensus estimate for 'Revenues- Animal Safety' stands at $54.65 million. The estimate suggests a change of -5.2% year over year.
View all Key Company Metrics for Neogen here>>>Neogen shares have witnessed a change of +5.4% in the past month, in contrast to the Zacks S&P 500 composite's +4.3% move. With a Zacks Rank #4 (Sell), NEOG is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .